Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24837000 | 0.94 | NPC1 (0.36) | NPC1PTGES | |
| SCHEMBL23482739 | 0.91 | NPC1 (0.39) | NPC1PTGES | |
| SCHEMBL25943105 | 0.86 | NPC1 (0.31) | NPC1PTGES | |
| SCHEMBL25062347 | 0.85 | NPC1 (0.35) | NPC1PTGES | |
| SCHEMBL22044444 | 0.80 | NPC1 (0.34) | NPC1PTGES | |
| SCHEMBL23901255 | 0.76 | NPC1 (0.33) | NPC1 | |
| SCHEMBL24872432 | 0.74 | NPC1 (0.34) | NPC1PTGES | |
| SCHEMBL23482676 | 0.73 | NPC1 (0.33) | NPC1 | |
| SCHEMBL24064973 | 0.68 | HPGD (0.36) | NPC1 | |
| SCHEMBL10044972 | 0.61 | GRIA1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873281-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2024-01-16 | — | — | US | disclosed |
| US-20210308277-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-10-07 | — | — | US | disclosed |
| US-20200172480-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873281-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | NPC1 2010/4885PTGES 4793/4885 |
| US-20200172480-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | CD4, CD2, CD47 | NPC1 2010/4885PTGES 4793/4885 |
| US-20210308277-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | CD2BP2, DCLRE1A, EPCAM | NPC1 3147/4885PTGES 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.